Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis
- 26 May 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 108 (2), 259-264
- https://doi.org/10.1007/s10549-007-9593-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Annals of Oncology, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerThe New England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast CancerJournal of Clinical Oncology, 2003
- Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective studyBreast Cancer Research and Treatment, 1997
- Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancerBreast Cancer Research and Treatment, 1994
- Feasibility and reproducibility of the [3H]‐thymidine labelling index in breast cancerCell Proliferation, 1991
- Characterization of Laboratory Working Standard for Quality Control of Immunometric and Radiometric Estrogen Receptor Assays. Clinical Evaluation on Breast Cancer BiopsiesTumori Journal, 1989
- Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancerInternational Journal of Cancer, 1989
- Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptorsBreast Cancer Research and Treatment, 1988